KLP Kapitalforvaltning’s BioMarin Pharmaceuticals BMRN Stock Holding History

KLP Kapitalforvaltning’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.36M	Hold	41,300	–	–	0.01%	700
2026 Q1	$2.33M	Hold	41,300	–	–	0.01%	655
2025 Q4	$2.45M	Sell	41,300 -29,237	-41%	-$1.59M	0.01%	636
2025 Q3	$3.82M	Hold	70,537	–	–	0.02%	532
2025 Q2	$3.88M	Buy	70,537 +1,200	+2%	+$70.7K	0.02%	520
2025 Q1	$4.9M	Buy	69,337 +2,600	+4%	+$175K	0.02%	483
2024 Q4	$4.39M	Buy	+66,737	New	+$4.47M	0.02%	509

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KLP Kapitalforvaltning's BMRN Position: Q2 2026 in Review

KLP Kapitalforvaltning held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 41,300 shares worth $2.36M. The position accounts for 0.01% of the portfolio, ranked #700.

KLP Kapitalforvaltning first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.9M in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

KLP Kapitalforvaltning held 41,300 shares of BioMarin Pharmaceuticals worth $2.36M as of Q2 2026.
KLP Kapitalforvaltning left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up 0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #700 holding.
KLP Kapitalforvaltning first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
KLP Kapitalforvaltning's BioMarin Pharmaceuticals position peaked at $4.9M in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.